Connect with us
DAPA Banner

Business

ImmunityBio (IBRX) Shares Drop Nearly 10% as Investors Digest Recent Earnings

Published

on

Coinbase Global

Shares of ImmunityBio Inc. (NASDAQ: IBRX) tumbled nearly 10% in heavy trading Wednesday, reflecting profit-taking after a strong run earlier in the week and broader market caution amid ongoing volatility in biotech stocks.

ImmunityBio
ImmunityBio

The stock closed at $9.02 on March 4, 2026, down $0.98 or 9.85% from Tuesday’s close of $10.00. Intraday trading saw the price range from a low of $8.93 to a high of $9.59, with volume exceeding 16.5 million shares — solid but below the 35 million-plus average seen in recent sessions. After-hours trading showed modest recovery attempts around $9.01-$9.10.

The pullback followed a volatile period: the shares surged to $10.44 on March 2 amid momentum from positive clinical updates, then eased to $10.00 on March 3 after the company’s full-year 2025 earnings release. Year-to-date in 2026, IBRX has more than quintupled from early lows around $1.83, driven by commercial traction for its flagship therapy ANKTIVA and advancing regulatory milestones.

ImmunityBio reported full-year 2025 results on March 3, highlighting a dramatic 700% year-over-year increase in net product revenue from ANKTIVA (nogapendekin alfa inbakicept-pmln), the IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The company expanded ANKTIVA approvals to additional indications, including lung cancer in select markets, and secured commercial partnerships in 33 countries with ongoing label expansion efforts globally.

Analysts responded positively, with Piper Sandler reiterating an Overweight rating and raising its price target to $15, citing strong sales momentum and regulatory progress. Consensus views lean toward “Strong Buy,” with an average 12-month target around $12.60 to $13.06, implying 30-40% upside from current levels. Some forecasts project highs up to $23-$25 if key milestones are met.

Advertisement

Key pipeline advances bolster the outlook. On Feb. 26, 2026, ImmunityBio announced completion of enrollment in the pivotal QUILT 2.005 randomized trial evaluating ANKTIVA plus BCG versus BCG alone in BCG-naïve NMIBC CIS patients. The study enrolled 366 patients ahead of schedule, with an interim analysis requested by the FDA showing statistically significant improvement in duration of complete response for the combination arm and no major safety issues. Full results are expected in Q4 2026, paving the way for a potential Biologics License Application (BLA) submission by year-end to expand ANKTIVA into the first-line setting.

The company also continues discussions with the FDA on a potential resubmission of its supplemental BLA for ANKTIVA in BCG-unresponsive papillary NMIBC. Following a January 2026 Type B End-of-Phase meeting, the agency requested additional supporting information but no new clinical trial. ImmunityBio compiled and planned to submit the data within 30 days, aiming to address prior refuse-to-file concerns without restarting studies.

An expanded access program for recombinant BCG remains active, with over 580 patients enrolled across the U.S., addressing supply shortages and supporting real-world evidence.

Despite the positive momentum, challenges persist. ImmunityBio reported ongoing net losses typical for a clinical-stage biotech, though revenue growth signals commercial viability. Cash position and burn rate remain focal points for investors, with the company emphasizing disciplined capital allocation toward pipeline advancement and global commercialization.

Advertisement

The stock’s 52-week range spans $1.83 to $12.43, with recent highs reflecting optimism around ANKTIVA’s potential to disrupt bladder cancer treatment landscapes — a market with significant unmet needs for durable responses beyond standard BCG therapy.

Market cap hovered near $9-10 billion following the dip, with about 1.03 billion shares outstanding. High short interest and retail investor interest have contributed to volatility, though recent trading has shown more stability tied to fundamentals.

As ImmunityBio eyes Q4 2026 data readouts and potential BLA filings, analysts watch for execution on manufacturing scale-up, partnership expansions, and additional indications. The biotech sector’s sensitivity to interest rates, regulatory timelines, and broader economic factors adds near-term uncertainty, but the company’s progress positions it as a notable player in immunotherapy.

Investors remain divided: bulls see multi-billion revenue potential if ANKTIVA secures broader approvals, while bears caution on competition and execution risks. For now, Wednesday’s decline appears more technical than fundamental, with many viewing the dip as a potential entry point amid the stock’s transformative trajectory.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Market, rupee fortunes may prove fickle amid Iran flareup

Published

on

Market, rupee fortunes may prove fickle amid Iran flareup
Mumbai: Markets are set to face fresh turmoil on Monday, with Iran closing the Strait of Hormuz because its ports were being blockaded by the US, forcing oil prices back up, in sharp contrast to the optimism on Friday, when the key maritime channel had been opened up.

Stocks and the rupee are seen facing fresh challenges after having recouped losses and strengthened amid easing geopolitical tensions. Last week, the Sensex and Nifty gained up to 1.3%, while broader indices advanced further – the Nifty Midcap 150 rose 3.5% and Smallcap 250 was up 4.4%, extending gains for the second straight week. The rebound faces hurdles if tensions erupt again.

The rupee may open 30-35 paise weaker against the dollar. It closed at 92.93 per dollar on Friday, up 0.30% from the previous close. But traders expect it to slip below 93 due to higher oil prices, after some ships were fired upon as Iran closed the Strait. Satellite imagery late on Sunday showed ships at a standstill, after they had started moving two days before.

“On Friday, things had cooled down a bit after Iran opened the Strait but since then, there have been some volatilities, as a result of which, oil prices have increased,” said Alok Singh, head of treasury at CSB Bank. “It is now turning out to be a market driven by statements from the US and Iran. We should expect volatility to continue till there is clarity.”

Advertisement

Belligerent statements by both sides are balanced by plans for renewed dialogue in Pakistan this week. Mediators and affected Gulf states are also keenly aware that the end of the two-week ceasefire is days away.

Screenshot 2026-04-20 060704Agencies

RBI may Help Rupee
“Based on the current news flow, markets on Monday are likely to react primarily to crude prices,” said Shrikant Chouhan, head of equity research, Kotak Securities. “If oil moves back toward $100 per barrel, the market may open near previous closing levels, and then shift focus toward domestic developments.”
When Iran announced on Friday that the Strait of Hormuz would be open as part of peace efforts, Brent crude plunged 9% to $90.38 a barrel, helping Wall Street benchmarks close at record highs later in the day. Before the US-Iran truce, prices were at around $110.
All eyes are on the diplomatic peace talks between the US and Iran, with the ceasefire deadline of April 22 fast approaching, said Siddhartha Khemka, head of research at Motilal Oswal Financial Services. “Now that there has been a sharp rally over the past 10 trading sessions, there should be some consolidation,” he said.

Higher oil prices will push the rupee to open lower on Monday before the Reserve Bank of India (RBI) possibly steps in to prevent a sharp fall, traders said. RBI’s move to take dollar demand by oil companies out of the market by providing them a direct supply of the currency through State Bank of India may also prevent a sharp fall in the rupee.

If the war continues for a longer period and crude again goes back to $100-120 per barrel, it will be negative for the economy, and markets could see a worse reaction, said Mahesh Ojha, vice president, research, Kantilal Chhaganlal Securities. “Fourth quarter results from ICICI are marginally better than expected, while HDFC Bank posted a steady quarter, and this could act as a positive trigger on Monday,” he said. “If conditions turn worse, the banking heavyweights could offer support, while if sentiment improves, they could add further upside.”

Since the ceasefire announcement on April 8, the Sensex and Nifty have gained over 5%, while the Nifty Midcap 150 and Nifty Smallcap 250 advanced roughly 10%.

Advertisement

The market seems well-positioned to extend its uptrend, rather than remain range-bound, said Dhupesh Dhameja, derivatives analyst at Samco Securities.

Continue Reading

Business

WrestleMania 42 Night 2: Has Brock Lesnar Retired?

Published

on

WWE WrestleMania 42 Night 2 - Brock Lesnar

It seems Brock Lesnar has retired.

Following his loss to Oba Femi during the second night of WrestleMania 42, Lesnar left his gloves and wrestling boots in the ring, a typical sign of retirement that fans last saw when AJ Styles retired in January.

Brock Lesnar Leaves Gloves, Boots in the Ring

Lesnar stayed seated in the ring after the match, soon shocking fans in attendance and watching at home when he began to remove his gloves. Fans soon began to voice their disapproval, continuously chanting “No!” as he went.

A visibly emotional and crying Lesnar then began to remove his boots before leaving them, along with the gloves, at the center of the ring.

Advertisement

Paul Heyman eventually entered the ring, and Lesnar made an “x” sign with his arms before the two shared a hug.

Lesnar waved to the crowd and bowed in gratitude before leaving the ring as chants of “Thank you, Lesnar” echoed throughout the arena.

Is This It for Lesnar?

If his actions in the ring truly meant that his match against Femi is his final match, Lesnar joins the list of recently-retired WWE legends.

It can be recalled that John Cena retired in December after tapping out to Gunther. AJ Styles likewise retired in January after a match with “The Career Killer.”

Advertisement

Fan reaction online has been swift as many grappled with the idea that Lesnar his retired, with many expressing their gratitude to one of the greatest combat athletes WWE has ever seen.

One fan on X expressed shock by saying, “4 minutes 45 seconds for what could be Brock’s last match??”

“Brock hasn’t retired yet,” another fan said. “We will see on Raw when Gunther confronts him.”

One pointed out a sad truth for a generation of WWE fans by saying, “Lesnar, Styles, & Cena all announced their retirement in the span of four months.”

Advertisement

Originally published on sportsworldnews.com

Continue Reading

Business

National Australia Bank hikes credit provisions on Iran war; flags $961 mln charge

Published

on


National Australia Bank hikes credit provisions on Iran war; flags $961 mln charge

Continue Reading

Business

CStone presents preclinical data on three ADC candidates at AACR

Published

on


CStone presents preclinical data on three ADC candidates at AACR

Continue Reading

Business

Traders ready to put war behind, dial up the risk

Published

on

Traders ready to put war behind, dial up the risk
Credit investors are loading up on riskier debt, betting that Iran and the US can extend their truce, and leaving behind havens they’ve favoured since the war broke out in late February.

In the first half of April, investors bought a net $500 million of bonds in the lowest tier of investment grade, and sold $7.3 billion of the higher tiers, according to JPMorgan Chase & Co. That helped BBB bonds perform comparatively better than higher-rated notes, pushing the gap between spreads for BBB and A corporates to the tightest since before the war.

There may be good reason for these slightly riskier bonds to be performing better: BBB rated companies have outperformed analysts’ average forecasts more than A companies have, according to a Bloomberg News analysis.

Buyers are hoping a more lasting peace in West Asia can be forged by negotiators, and that companies in the lower edges of investment grade can keep performing well.

Advertisement

“There is some value in the BBB space and issuers there have been good stewards of the balance sheet and generally improving credit quality,” said Gene Tannuzzo, global head of fixed income at Columbia Threadneedle Investments.


Investors have also been snatching up junk bonds, although with a preference for the higher-rated end of the spectrum, implying that money managers still see risk ahead even as they grow moderately more hopeful. Overall spreads for junk bonds are at their tightest since the war began, averaging 2.72% as of Thursday’s close.

Continue Reading

Business

Nifty has a bit of momentum, but faces resistance at 24,300-24,700

Published

on

Nifty has a bit of momentum, but faces resistance at 24,300-24,700
Technical signals suggest the recent rebound on Dalal Street is gathering traction, but conviction remains key. Analysts broadly see the market attempting to transition from a corrective phase to a more durable uptrend, supported by improving momentum and selective buying interest. However, they caution that the move is still at a critical juncture, with resistance zones likely to test the strength of the recovery.

ROHAN SHAH
TECHNICAL ANALYST, ASIT C MEHTA INVESTMENT

Where is Nifty headed this week?
Nifty staged a strong comeback this month after a prolonged four-month decline, supported by easing geopolitical tensions and lower crude prices. The index has approached a resistance band of 24,300–24,700, which aligns with multiple technical studies. However, sustained strength above this zone is essential for the continuation of the upward momentum, potentially paving the way toward 25,500. Inability to hold above this zone may trigger profit booking, dragging the index lower towards 23,500–23,200. Trading Strategy: Buy Nifty futures above 24,700 for an upside target of 25,500, maintaining a stop-loss below 24,250.

TOP STOCK BETS
Jubilant FoodWorks
Buy at CMP Rs 459 | Stop-loss Rs 420 | Target Rs 525
The stock shows early reversal signs, backed by one-year high volumes and a high-wave candle near a demand zone, indicating selling exhaustion. The Rs 420–440 zone is key support; RSI shows bullish divergence.
Maruti Suzuki India
Buy at CMP Rs 13,453 | Stop-loss Rs 12,500 | Target Rs 15,500

The stock has witnessed a strong rebound after confirming a bullish ABCD harmonic pattern. The formation of a cup-and-handle pattern alongside improving volumes signals accumulation. RSI holding above its breakout level suggests a positive bias.

Advertisement
Nifty has a Bit of Momentum, but Faces Resistance at 24,300-24,700Agencies

AJIT MISHRA
SVP – RESEARCH, RELIGARE BROKING

Where is Nifty headed this week?
Nifty is now approaching key moving averages (100 and 200 DEMA) in the 24,600– 24,800 zone. Sustained strength above this band could open room for further upside towards 25,200. In case of profit booking or consolidation, the 23,700–24,000 zone is likely to provide strong support.

Trading Strategies: For the short term, traders may consider a “buy on dip” approach in the 24,150–24,250 range, with a stop-loss at 23,900 and potential targets of 24,800 and 25,200. Among sectoral themes, the Nifty Energy Index has witnessed a fresh breakout after spending more than one-anda-half years in a consolidation phase. Participants can consider playing this theme through an ETF, i.e., Mirae Asset Nifty Energy ETF. It is currently trading at Rs 39.11, and one can accumulate it in the Rs 37–40 zone with a stoploss at Rs 34 for a positional target of Rs 52.

TOP STOCK BETS
Federal Bank Buy. CMP Rs 293 | Stop-loss Rs 278 | Target Rs 325

Federal Bank is in a steady uptrend with higher highs and lows post-base formation. A strong breakout near the 200-DMA signals a sentiment shift; price holds above key averages, with RSI supporting continuation.

Advertisement

JSW Energy
Buy. CMP Rs 538 | Stop-loss Rs 504 | Target Rs 598

JSW Energy is in a stage-2 uptrend, consolidating after a strong rally. The range-bound move near the 200-DMA suggests a healthy pause, with price now attempting an upward breakout supported by improving momentum.

RAJESH PALVIYA
HEAD OF TECHNICAL AND DERIVATIVES, AXIS SECURITIES

Where is Nifty headed this week?
Nifty is fast approaching 24,415—the upper boundary of the bearish gap etched on March 9. A conviction close above 24,500, however, could open the floodgates. The next logical pit stops are 24,762— the 61.8% Fibonacci retracement of the Feb March decline—and the psychologically significant 25,000 mark. A slip below the 24,000–23,900 support band would be a warning shot, potentially dragging the index back to retest its weekly low of 23,555. Traders on the long side would do well to respect this floor. The overall outlook remains positive, as the weekly RSI continues to stay above its reference line. This indicates that positive momentum is still intact and not yet exhausted.

Advertisement

Trading Strategies: The recommended strategy for Nifty options for the April 28, 2026, expiry is a call spread, ideal for a moderately bullish market outlook. The trader buys one lot of the 24,400-strike Call option at a premium of Rs 260–240 and simultaneously sells one lot of the 24,700-strike Call option at a premium of Rs 130–150. This strategy limits both risk and reward, creating a defined range for outcomes. The break-even point is at 24,530, with a maximum potential loss of Rs 8,450 and a maximum profit of Rs 11,050.

TOP STOCK BETS
Mazagon Dock Shipbuilders
Buy at Rs 2,618, CMP Rs 2,620| Stop-loss Rs 2,550 | Target Rs 2,800-2,850

A breakout above Rs 2,430 signals a shift to a primary uptrend, with RSI strength confirming bullish momentum. Resistance lies at Rs 2,800–2,850; sustained strength could extend gains to Rs 3,000–3,050.

Polycab India
Buy at Rs 8,184, CMP Rs 8,188.50 | Stop-loss Rs 7,900 | Target Rs 8,600-8,900

Advertisement

An uptrend supported by a rising trendline and a doublebottom near Rs 6,650 underpins strength. Resistance at Rs 8,700; a breakout could target Rs 9,000+. Maintain Rs 7,600 as a stop-loss; below this, risks a breakdown.

Continue Reading

Business

AMD: $600 Bullseye (NASDAQ:AMD) | Seeking Alpha

Published

on

AMD: $600 Bullseye (NASDAQ:AMD) | Seeking Alpha

This article was written by

Stone Fox Capital is an RIA from Oklahoma. Mark Holder is a CPA with degrees in Accounting and Finance. He is also Series 65 licensed and has 30 years of investing experience, including 15 years as a portfolio manager. Mark leads the investing group Out Fox The Street where he shares stock picks and deep research to help readers uncover potential multibaggers while managing portfolio risk via diversification. Features include various model portfolios, stock picks with identifiable catalysts, daily updates, real-time alerts, and access to community chat and direct chat with Mark for questions. Learn more.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock, you should do your own research and reach your own conclusion or consult a financial advisor. Investing includes risks, including loss of principal.

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Modular Medical prices $3.4 million stock offering at $4.50/share

Published

on


Modular Medical prices $3.4 million stock offering at $4.50/share

Continue Reading

Business

Oil prices jump as Strait of Hormuz tensions escalate

Published

on

Oil prices jump as Strait of Hormuz tensions escalate

Energy markets have seen wild swings since the US and Israel attacked Iran on 28 February.

Continue Reading

Business

Monopar presents Phase 3 Wilson disease trial data at AAN meeting

Published

on


Monopar presents Phase 3 Wilson disease trial data at AAN meeting

Continue Reading

Trending

Copyright © 2025